SHALBY · NSE
Shalby Limited
₹137.66
-0.61% (-₹0.84)
Prev. close
₹138.5
Volume
1,49,630
Delivery %
56.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Shalby Limited
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, Paediatric orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; interventional and diagnostic radiology; and robotic joint replacement. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Daniel Hayes
Headquarters
Ahmedabad
Employees
2,217
Website
shalby.orgExchange
View on NSE ↗Key stats
Market cap
₹1,495.70 Cr
P/E ratio (TTM)
39.7
EPS (TTM)
₹3.50
Beta (1Y · daily vs NIFTY 50)
1.45
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
2.67 Cr
EPS · quarter ended Jun 2026
₹0.98
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹418.67 Cr | ₹698.95 Cr | ₹804.92 Cr | ₹933.75 Cr | ₹1,086.96 Cr | ₹1,141.43 Cr | |
| EBITDA | ₹95.74 Cr | ₹127.92 Cr | ₹158.10 Cr | ₹196.47 Cr | ₹160.20 Cr | ₹169.54 Cr |
| ₹42.88 Cr | ₹53.97 Cr | ₹67.70 Cr | ₹84.08 Cr | ₹6.22 Cr | ₹37.39 Cr | |
| Diluted EPS | ₹3.97 | ₹5 | ₹6.27 | ₹7.77 | ₹0.18 | ₹3.23 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹996.63 Cr | ₹1,193.54 Cr | ₹1,281.36 Cr | ₹1,607.53 Cr | ₹1,703.65 Cr | ₹1,839.13 Cr | |
| — | ₹174.07 Cr | ₹180.51 Cr | ₹377.87 Cr | ₹475.93 Cr | ₹594.59 Cr | |
| Stockholders' equity | ₹834.66 Cr | ₹876.32 Cr | ₹927.69 Cr | ₹1,000.37 Cr | ₹992.19 Cr | ₹1,005.23 Cr |
Current assets, Receivables (trade + unbilled), Trade receivables, Unbilled receivables (contract assets), Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹82.45 Cr | ₹18.89 Cr | ₹67.77 Cr | ₹19.60 Cr | ₹-4.34 Cr | ₹-1.20 L | |
| Investing cash flow | ₹-57.54 Cr | ₹-60.26 Cr | ₹-61.06 Cr | ₹38.07 Cr | ₹-35.64 Cr | ₹-97.28 Cr |
| ₹-27.32 Cr | ₹90.46 Cr | ₹-50.02 Cr | ₹-150.69 Cr | ₹47.58 Cr | ₹84.41 Cr | |
| Capital expenditure | ₹-26.51 Cr | ₹-75.37 Cr | ₹-18.48 Cr | ₹-47.11 Cr | ₹-71.45 Cr | ₹-149.05 Cr |
| End cash position | ₹6.48 Cr | ₹55.58 Cr | ₹12.24 Cr | ₹27.18 Cr | ₹34.79 Cr | ₹21.90 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22–Sep 22(2Q) | Dec 22–Sep 23(4Q) | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24–Jun 25(3Q) | Sep 25–Dec 25(2Q) | Mar 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.02% | 74.04% | 74.12% | 74.12% | 74.24% | 74.25% | 74.25% | 74.27% | 74.33% | 74.33% |
| Public | 25.05% | 25.04% | 25.01% | 25.05% | 25.01% | 25.05% | 25.06% | 25.04% | 25.01% | 25.02% |
| Employee trusts | 0.93% | 0.93% | 0.87% | 0.83% | 0.76% | 0.70% | 0.69% | 0.69% | 0.66% | 0.66% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Shalby Limited | ₹1,495.70 Cr | ₹137.66 | 39.7 | 1.49 | 3.7% | 0.59 | +5.0% | -41.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Shalby Gurgaon hospital turns profitable for the first time since acquisition
Business Upturn · 1 month ago